Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).Julie E. Bauman, Robert L. Ferris, D.A. Clump et al.|Journal of Clinical Oncology|2014Cited by 11